270 related articles for article (PubMed ID: 12182229)
1. HMG-Co A reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaque.
Morishita R; Tomita N; Ogihara T
Curr Drug Targets; 2002 Oct; 3(5):379-85. PubMed ID: 12182229
[TBL] [Abstract][Full Text] [Related]
2. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
Sadowitz B; Maier KG; Gahtan V
Vasc Endovascular Surg; 2010 May; 44(4):241-51. PubMed ID: 20403949
[TBL] [Abstract][Full Text] [Related]
3. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
Fujita R; Matsushima T
Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
[TBL] [Abstract][Full Text] [Related]
4. [Inhibitors of HMG CoA reductase: new modes of action, new indications?].
Essig M; Vrtovsnik F; Friedlander G
Therapie; 2000; 55(1):43-9. PubMed ID: 10860000
[TBL] [Abstract][Full Text] [Related]
5. Statins: effective antiatherosclerotic therapy.
Blumenthal RS
Am Heart J; 2000 Apr; 139(4):577-83. PubMed ID: 10740137
[TBL] [Abstract][Full Text] [Related]
6. [Statins: possibly more than just lowering of the lipid level].
Visseren FL; Lansberg PJ; Erkelens DW; Kastelein JJ
Ned Tijdschr Geneeskd; 2000 Feb; 144(7):316-21. PubMed ID: 10707742
[TBL] [Abstract][Full Text] [Related]
7. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
9. Genetic determinants of response to statins.
Peters BJ; Klungel OH; de Boer A; Maitland-van der Zee AH
Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):977-83. PubMed ID: 19673675
[TBL] [Abstract][Full Text] [Related]
10. Beneficial cardiovascular pleiotropic effects of statins.
Davignon J
Circulation; 2004 Jun; 109(23 Suppl 1):III39-43. PubMed ID: 15198965
[TBL] [Abstract][Full Text] [Related]
11. [Pleiotrophic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors)].
Igel M; Sudhop T; von Bergmann K
Arzneimittelforschung; 2003; 53(8):545-53. PubMed ID: 13677244
[TBL] [Abstract][Full Text] [Related]
12. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
[TBL] [Abstract][Full Text] [Related]
13. Statins: the new aspirin?
Veillard NR; Mach F
Cell Mol Life Sci; 2002 Nov; 59(11):1771-86. PubMed ID: 12530513
[TBL] [Abstract][Full Text] [Related]
14. The evolving role of statins in the management of atherosclerosis.
Vaughan CJ; Gotto AM; Basson CT
J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252
[TBL] [Abstract][Full Text] [Related]
15. [The promise of statins].
Capurso A
Ital Heart J Suppl; 2001 Mar; 2(3):224-9. PubMed ID: 11307780
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of pleiotropic effects of statins: lipid reduction and beyond.
Auer J; Berent R; Weber T; Eber B
Curr Med Chem; 2002 Oct; 9(20):1831-50. PubMed ID: 12369881
[TBL] [Abstract][Full Text] [Related]
17. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography.
Callister TQ; Raggi P; Cooil B; Lippolis NJ; Russo DJ
N Engl J Med; 1998 Dec; 339(27):1972-8. PubMed ID: 9869668
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin treatment prevents alterations in coronary smooth muscle nuclear Ca2+ signaling in diabetic dyslipidemia.
Wamhoff BR; Dixon JL; Sturek M
J Vasc Res; 2002; 39(3):208-20. PubMed ID: 12097819
[TBL] [Abstract][Full Text] [Related]
19. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.
Koh KK
Cardiovasc Res; 2000 Sep; 47(4):648-57. PubMed ID: 10974215
[TBL] [Abstract][Full Text] [Related]
20. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rosenson RS
Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
